甲磺酸伊马替尼辅助治疗原发胃肠间质瘤29例

Adjuvant Imatinib Mesylate Treatment after Resection in 29 Cases of Localized Primary Gastrointestinal Stromal Tumours

目的研究局灶、原发胃肠间质瘤切除术后甲磺酸伊马替尼辅助治疗是否能够改善无复发生存时间。方法采用前瞻性方法对2007年1月～2008年11月由第二军医大学附属长海医院收治的29例局灶、原发胃肠间质瘤切除术后患者给予口服甲磺酸伊马替尼400mg，1次／日，用药1年以上（高危患者2年以上）。计算1年及2年无复发生存率。结果所有患者均纳入统计学分析，中位随访时间33．9个月（24—48个月），1年及2年无复发生存率均为100％。结论甲磺酸伊马替尼辅助治疗安全可靠，手术切除局限、原发胃肠间质瘤后，使用甲磺酸伊马替尼辅助治疗有可能改善术后无复发生存时间。

Objective To inverstigate whether adjuvant treatment with imatinib mesylate could improve recurrence -free survival （RFS） or not. Methods From January 2007 to November 2008, 29 cases of localized, primary gastrointestinal stromal tumours received imatiuib mesylate 400 mg/day for at least one year following surgical resection（ at least two year for high - risk GIST）. The primary end- point was RFS at 1 year and RFS at 2 year. Results All randomized patients were included in the analysis. At median follow - up of 33. 9 months （ minimum - maximum 24 - 48 months） , both RFS at 1 year and RFS at 2 year was 100%. Conclusion Adjuvant imatinib mesylate treatment was well - tolerated with a low rate of serious adverse events. Adjuvant imatinib mesylate therapy may improve RFS following the resection of primary GIST.